How Crohn's is treated: the big picture
Calming a flare, keeping it calm, step-up versus top-down, and where UK guidelines disagree
In short
- Treatment has two jobs: settling a flare (induction) and keeping Crohn's quiet afterwards (maintenance).
- The main medicine groups are steroids, immunosuppressants, biologics and newer targeted tablets.
- 'Step-up' starts with simpler medicines; 'top-down' starts a biologic early. A UK trial found early infliximab led to better results for newly diagnosed people.
- NICE's Crohn's guideline dates from 2019; the British Society of Gastroenterology (BSG) updated its advice in 2025, and the two differ on several points.
- Your IBD team will tailor treatment to you. Never stop or change a medicine without talking to them.
On this page
Can Crohn's be cured?
Not yet. The NHS explains that there is currently no cure, but treatment can keep many people free of symptoms for long stretches of time. Doctors call this remission. Most people need different treatments at different points in their life, and you will usually be looked after by a team that includes a gut specialist (gastroenterologist), with regular check-ups and tests.1
The NHS lists four broad kinds of medicine: ones that calm inflammation in the gut (such as steroids), ones that turn down the immune system (immunosuppressants such as azathioprine), ones that target a specific part of the immune system (biologics such as adalimumab or infliximab), and ones that ease symptoms such as pain or diarrhoea. A special liquid-only diet may be offered instead of medicine, especially for children or people who cannot have steroids. Surgery may be an option when only one part of the gut is affected, or when symptoms are severe and medicines are not working.1
Why are there two stages of treatment?
Doctors think of treatment in two parts. The first is getting a flare under control, which is called inducing remission. The second is keeping it under control, which is called maintaining remission. Some medicines are good at one job but not the other. Steroids, for example, can calm a flare quickly but should not be used to keep Crohn's quiet over the long term.23
NICE's 2019 guideline describes a step-by-step plan. For a first flare, or a single flare in a year, it says to offer a standard steroid such as prednisolone. Budesonide (a steroid that acts mainly in the gut) or a 5-ASA medicine may be considered for some people who cannot have standard steroids, and a liquid diet may be considered for children or young people when growth is a worry. NICE advises against using azathioprine, mercaptopurine or methotrexate on their own to settle a flare, but suggests adding azathioprine or mercaptopurine if someone has two or more flares in a year or cannot come off steroids.3
Once Crohn's is calm, NICE says doctors should talk through the options, including having no maintenance treatment at all, and record what the person prefers. For people who choose treatment, NICE suggests azathioprine or mercaptopurine, with methotrexate for those who cannot take them. It says steroids and budesonide should not be used to keep Crohn's in remission.3
What are the main groups of medicine?
- Steroids (corticosteroids) such as prednisolone and budesonide: a short-term treatment for flares.
- Immunosuppressants (also called immunomodulators) such as azathioprine, mercaptopurine and methotrexate: tablets or injections that turn down the whole immune system and are mainly used to keep Crohn's calm.
- Biologics: antibody medicines made by living cells in a lab, given by drip or injection. They include the anti-TNF medicines infliximab and adalimumab, the gut-targeted medicine vedolizumab, and medicines that block interleukins (ustekinumab, risankizumab, mirikizumab and guselkumab).
- Targeted tablets (small molecules) such as upadacitinib, a JAK inhibitor that is made by chemical processes rather than by living cells.2456
Crohn's & Colitis UK explains that biologics and targeted tablets block particular proteins or chemical pathways that drive inflammation, so they are more precise than older immunosuppressants. Because those pathways are part of the immune system, all of these medicines can make infections more likely.4
What do 'step-up' and 'top-down' mean?
Step-up means starting with simpler treatments, such as steroids and immunosuppressants, and only moving to a biologic if those do not work. Top-down means starting a biologic early, usually infliximab together with an immunosuppressant, to get inflammation under control before it causes lasting damage.78
The UK PROFILE trial compared the two approaches in people newly diagnosed with Crohn's. Starting infliximab with an immunosuppressant from the beginning led to more people being in remission without steroids or surgery at 48 weeks. Follow-up over about five years found far fewer Crohn's operations in the top-down group: six operations, compared with 28 in the step-up group.789
Crohn's & Colitis UK notes that some specialists have started to use this early approach, while others prefer to follow existing guidelines while the research is reviewed. A review of the 2025 BSG guideline says it is likely, but not yet proven, that the same benefit applies to other advanced medicines, and that the role of top-down treatment in mild Crohn's is unknown.710
Where do NICE and the BSG disagree?
Two main sets of UK guidance cover Crohn's treatment. NICE's guideline (NG129) was last updated in 2019, and NICE has also published separate appraisals of individual medicines. The British Society of Gastroenterology, the UK's specialist body for gut doctors, published new guidelines in 2025. Because the BSG advice is newer, it reflects recent trials, and in several places it differs from NICE.71112
- Starting a biologic early: NICE recommends infliximab or adalimumab for severe Crohn's once standard treatments have not worked. The BSG says infliximab should be started early for moderate to severe Crohn's.
- Immunosuppressants on their own: NICE suggests azathioprine or mercaptopurine alone to keep Crohn's calm. The BSG no longer suggests azathioprine, mercaptopurine or methotrexate on their own for moderate to severe Crohn's, although it says people already doing well on them should not have them stopped without a discussion first.
- Combining medicines: NICE says to discuss using infliximab or adalimumab alone or with an immunosuppressant, and to explain that it is uncertain which is better. The BSG recommends starting infliximab or adalimumab together with a thiopurine to lower the chance of the body making antibodies against the biologic.
- Vedolizumab: NICE recommends it after an anti-TNF medicine has failed or is unsuitable. The BSG no longer suggests it for moderate to severe Crohn's because trials showed only a small effect, although it may still suit some people.
- After bowel surgery: NICE suggests azathioprine, with up to three months of the antibiotic metronidazole, and says biologics should not be offered after a complete removal of the diseased bowel. The BSG suggests everyone who has had an ileocaecal resection should be offered early advanced treatment, starting with infliximab, adalimumab or vedolizumab.
- Steroids: both use steroids to settle flares, but the BSG specifically warns against long or repeated courses because of their side effects.371314
NICE's medicine appraisals still decide which treatments the NHS in England has to fund. NICE's more recent appraisals say that once it recommends a medicine, the NHS in England must fund it within 30 days. Your IBD team will weigh up both sets of advice, alongside your own situation, when suggesting a plan.1516
What does 'treat to target' mean?
Treat to target means agreeing clear goals with your IBD team and adjusting treatment until you reach them, rather than stopping once you feel a bit better. An international expert group called STRIDE-II set out the goals. In the short term these are relief of symptoms and normal results on blood and poo tests, such as CRP and calprotectin. In the longer term they are a healed gut lining when seen with a camera (endoscopy), no disability, a good quality of life and, for children, normal growth.17
How is a biologic or targeted medicine chosen?
There are now several advanced medicines for Crohn's, and nobody can yet predict which one will work best for a particular person. Crohn's & Colitis UK suggests thinking about how each one is given, how often, how quickly it works, its side effects, what checks it needs and whether it might also help joint or skin problems. Your IBD team should review any biologic or targeted medicine at least once a year.4
Cost is part of the decision. In several of its appraisals, NICE says that when more than one medicine is suitable, the choice should be made with the patient after discussing the pros and cons, and the least expensive suitable option should be used.16181920
Each medicine has its own page in this hub, covering how it works, how it is given, the checks you need and the side effects listed by the NHS and Crohn's & Colitis UK. They are a starting point for a conversation with your IBD team, not a replacement for it.14
Sources
This article is written in our own words from these sources. Each number in the text points to one of them.
- NHS Crohn's disease Web page, Dec 2023 Read on the NHS website: Crohn's disease
- Crohn's & Colitis UK Steroids Guide, Aug 2026 Read on the Crohn's & Colitis UK website: Steroids
- NICE Crohn's disease: management - Recommendations Guideline, May 2019 Read on the NICE website: Crohn's disease: management - Recommendations
- Crohn's & Colitis UK Biologic medicines and other targeted treatments Guide, Jul 2023 Read on the Crohn's & Colitis UK website: Biologic medicines and other targeted treatments
- Crohn's & Colitis UK Azathioprine and mercaptopurine Guide, Jun 2024 Read on the Crohn's & Colitis UK website: Azathioprine and mercaptopurine
- Crohn's & Colitis UK Methotrexate Guide, Mar 2023 Read on the Crohn's & Colitis UK website: Methotrexate
- Frontline Gastroenterology (via PMC) Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 1: Crohn's disease Guide, Nov 2025 Read the paper: Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 1: Crohn's disease
- The Lancet Gastroenterology & Hepatology A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE) Study, May 2024 Read the paper: A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE)
- The Lancet Gastroenterology & Hepatology Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial Study, Nov 2026 Read the paper: Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial
- Crohn's & Colitis UK Infliximab Guide, Jun 2024 Read on the Crohn's & Colitis UK website: Infliximab
- NICE Crohn's disease: management (NG129) Guideline, May 2019 Read on the NICE website: Crohn's disease: management (NG129)
- British Society of Gastroenterology British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025 Guideline, Jun 2025 Read on the British Society of Gastroenterology website: British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025
- NICE Infliximab and adalimumab for the treatment of Crohn's disease (TA187) Guideline, May 2010 Read on the NICE website: Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
- NICE Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352) Guideline, Aug 2015 Read on the NICE website: Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)
- NICE Mirikizumab for previously treated moderately to severely active Crohn's disease (TA1080) Guideline, Jul 2025 Read on the NICE website: Mirikizumab for previously treated moderately to severely active Crohn's disease (TA1080)
- NICE Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095) Guideline, Aug 2025 Read on the NICE website: Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)
- Gastroenterology STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD) Guideline, Apr 2021 Read on the Gastroenterology website: STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD)
- NICE Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456) Guideline, Jul 2017 Read on the NICE website: Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)
- NICE Risankizumab for previously treated moderately to severely active Crohn's disease (TA888) Guideline, May 2023 Read on the NICE website: Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)
- NICE Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905) Guideline, Jun 2023 Read on the NICE website: Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)